April 2026 Research Update

What this month showed

This month added several early signals that targeted immune therapies may help some people with difficult-to-treat dermatomyositis problems, especially lung disease linked to anti-MDA5 antibodies and severe skin symptoms. The strongest human evidence here is an observational comparison suggesting upadacitinib and tofacitinib had similar short-term outcomes in anti-MDA5 dermatomyositis with interstitial lung disease. Other reports included small studies and single-patient experiences, which can provide early signals but cannot tell us reliably how often a treatment will work. [1] [2] [3] [4]

In anti-MDA5 dermatomyositis with interstitial lung disease, a multicenter study compared upadacitinib with tofacitinib and found upadacitinib was non-inferior for 6-month lung-transplant-free survival, with similar reported safety profiles between groups. This supports the idea that more than one JAK inhibitor (a drug class that affects immune signaling) may be used in this setting, but it does not prove one is better. Because this was not a randomized trial, differences between patient groups could still influence the results. [1]

Smaller studies helped connect treatments to measurable changes in muscle or skin inflammation. A post hoc analysis from a 12-week open-label tofacitinib study reported that a specialized MRI measure (ADC, a number reflecting water movement in tissue) decreased in some muscles that were swollen at baseline, and in some patients this change matched muscle-strength improvement. This points toward imaging as a possible way to track muscle inflammation more objectively, but it remains an early finding from a small group. [3]

For skin-predominant or refractory disease, single-patient reports described improvement with newer targeted options. One case described near resolution of long-standing refractory skin lesions with deucravacitinib (a TYK2 inhibitor, which affects immune pathways related to interferon and inflammation). Another mechanistic study in photosensitive dermatomyositis included a small proof-of-concept experience where anifrolumab (a type I interferon-blocking antibody) was reported to reduce photosensitivity and prevent UVB-triggered inflammatory cell entry into skin. [4] [5]

There were also individual case reports describing add-on approaches in severe lung disease. One patient with anti-MDA5 dermatomyositis-associated interstitial lung disease improved after adding upadacitinib after prior intensive therapy did not control progression, though infections occurred and were managed. Another paper mentioned baricitinib use in TIF1-gamma positive dermatomyositis after COVID-19 infection, but the available summary did not include outcomes, so no conclusions can be drawn from it. [2] [6]

What this means in daily life

These studies mainly add near-term understanding rather than changing what is known to work for everyone. For anti-MDA5 lung disease, the comparison of upadacitinib and tofacitinib suggests the two treatments may perform similarly over 6 months, which may matter later if confirmed in other settings. For muscle and skin disease, the newer information is that researchers are trying to match targeted drugs with measurable changes in inflammation (including MRI signals and UV-triggered skin reactions), but this is still early research. What remains uncertain is who benefits most, how durable improvements are, and how to balance benefits against risks like infections in people needing strong immune suppression. [1] [3] [5] [2]

What this month showed

This month sharpened the picture that dermatomyositis-related interstitial lung disease, especially anti-MDA5 disease, can vary widely from stable to rapidly worsening, and that risk can be estimated using a mix of clinical features, blood tests, and imaging. Several studies focused on predicting who is more likely to develop rapidly progressive ILD or poorer outcomes, while others described what severe disease looks like in lung tissue or after complications. Taken together, these studies move the field toward clearer risk stratification rather than a one-size-fits-all view of lung involvement. [7] [8] [9]

In anti-MDA5 dermatomyositis-associated ILD, multiple groups built prediction tools that combine readily available information into an estimated risk. One multicenter study reported a nomogram for overall survival using rapidly progressive ILD, age, ESR (a general inflammation blood test), and neutrophil-to-lymphocyte ratio. Another large cohort across age groups highlighted that cough, shortness of breath, Pneumocystis jirovecii pneumonia (PJP), and rapidly progressive ILD were more common with older age, and incorporated age and PJP into a mortality nomogram. [7] [9]

A systematic review and meta-analysis pulled together earlier studies on what predicts rapidly progressive ILD in anti-MDA5 dermatomyositis-associated ILD. It reported higher odds of rapidly progressive ILD with factors such as older age, fever, anti-Ro52 antibody positivity, and higher inflammation-related labs (for example CRP, neutrophil-to-lymphocyte ratio, LDH, and ferritin). It also reported some factors linked with lower odds, such as joint pain or arthritis, which helps show that anti-MDA5 disease can present in different patterns. [8]

Several studies focused on very severe lung involvement to clarify what it looks like and what might predict poor short-term outcomes. In a small case series of anti-MDA5 ILD complicated by spontaneous pneumomediastinum (air leak into the chest), the report described very high short-term mortality and noted that higher CT-based scores and higher ferritin and LDH were seen in those who died, while the only survivor had a lower CT score. Another series examining explanted lungs from anti-MDA5 patients with rapidly progressive ILD found diffuse alveolar damage (an acute lung injury pattern) in all cases, and emphasized that this may be hard to detect on small lung biopsies. [10] [11]

Not all lung-related research was about anti-MDA5, and not all outcomes were poor. A Canadian multicenter study of lung transplantation in autoimmune-related ILD reported that people with idiopathic inflammatory myopathy had similar survival to those transplanted for idiopathic pulmonary fibrosis, and no autoimmune disease recurrence was observed, although ICU and hospital stays were longer in the myositis group. This helps frame transplantation as an area where outcomes can be comparable even when pre-transplant illness is complex. [12]

One biomarker study suggested a possible blood-based way to flag ILD risk within myositis, though it is not ready for routine use. In a cross-sectional study of dermatomyositis and polymyositis, endothelin-1 (ET-1) was higher in patients than controls and higher in those with ILD than those without ILD, and ET-1 correlated with cell-free DNA. The study also reported a combined model with good diagnostic performance for identifying ILD, but cross-sectional data cannot show whether ET-1 rises before ILD develops. [13]

What this means in daily life

For patients, the main new message is that researchers are getting better at describing which features cluster with higher-risk lung disease in dermatomyositis, especially in anti-MDA5 disease. Some of these features are practical (age, certain symptoms, infections like PJP), and some are test-based (simple inflammation blood tests and CT scoring). This may matter later if prediction tools are validated across different hospitals and countries and if they are shown to improve decision-making. What remains uncertain is how well any single score predicts an individual person's course, and which combinations of markers best capture risk early enough to be useful. [7] [9] [8] [10] [13]

What this month showed

This month strengthened the idea that dermatomyositis is not one uniform condition, and that measurement tools and lab or imaging markers can capture different sides of the disease. Several studies focused on better tracking in juvenile dermatomyositis, including what parents report and how children perform on simple movement tasks. Other studies focused on diagnostic markers in tissue or imaging that may help when symptoms or antibody tests do not give a clear answer. [14] [15] [16]

In juvenile dermatomyositis, 2 studies emphasized that functional ability and lived experience can add information beyond standard clinic measures. A parent-reported score (ParJDMAI) was validated in a large multicenter cohort and showed good reliability and responsiveness, supporting its potential use for tracking changes over time, including remotely. A separate longitudinal cohort found that simple performance tests (broad jump and a 10-meter run) correlated with disease activity and muscle function, and also showed that some children labeled clinically inactive still had reduced performance, suggesting recovery can be uneven across different types of measures. [14] [15]

Several diagnostic studies examined tools that could support dermatomyositis diagnosis when there is overlap with other muscle diseases. In muscle biopsies, MxA protein staining was seen in a subset of inflammatory myopathy cases including dermatomyositis, and was not seen in the same way in hereditary muscle diseases, suggesting it can help differentiate conditions in some settings. Another study of tissue samples reported that certain dendritic cell patterns and MDA5 expression differed in dermatomyositis compared with a rheumatoid arthritis lung disease comparison group, proposing a potential diagnostic clue and a possible link to fibrosis. [16] [17]

Imaging studies continued to explore how scans can support diagnosis and monitoring. In a study spanning multiple muscle diseases, dermatomyositis tended to show muscle swelling (edema) on MRI without a fixed pattern, contrasting with more stereotyped patterns in some other myopathies. In a small pediatric series, EOS 2D/3D imaging detected calcinosis locations that were missed by physical exam or standard X-rays in every patient studied, although upper-extremity deposits were missed in some cases due to positioning. [18] [19]

Population studies also described how dermatomyositis and related myositis conditions look across groups of people, which can influence recognition. In a Hispanic cohort, dermatomyositis was the most common idiopathic inflammatory myopathy subtype, most patients had mild skin activity, and distinct clinical-serology groupings were reported. A separate genetic study reported that an IL1B gene variant (rs16944) was associated with risk of idiopathic inflammatory myopathies across several subtypes, but this does not yet translate into a clinical test for individuals. [20] [21]

One systematic review looked for evidence supporting a treat-to-target approach in juvenile dermatomyositis and found no studies that directly compared a targeted strategy with conventional management. What it did add was a clearer map of what endpoints have been discussed in the literature and when they might be expected, even though evidence quality varied widely across articles. [22]

What this means in daily life

For families dealing with juvenile dermatomyositis, this month adds more support for measuring health in ways that reflect daily function and fatigue, not only what is seen in a clinic exam. For diagnosis, the studies suggest that combining information from antibodies, biopsy markers, and imaging can be helpful when presentation is atypical or overlaps with other muscle diseases, but many of these tools still need broader validation. What remains uncertain is which new markers will become widely available and how well they perform in different labs and patient populations. For now, these findings mainly add understanding of how dermatomyositis can be tracked and distinguished rather than providing a single definitive test. [14] [15] [16] [17] [19]

What this month showed

This month’s case reports highlighted how varied dermatomyositis can be, including atypical symptoms, overlapping antibodies, unexpected infections, and cancer-linked presentations. Across the cases, a repeated message was that antibodies and careful imaging or biopsy interpretation can matter when the picture is not straightforward. Because these are individual cases or very small series, they show what is possible rather than what is typical. [23] [24] [25]

Several cases described unusual antibody combinations or presentations that complicated diagnosis. One man had a rare combination of anti-MDA5 antibodies (often seen in dermatomyositis with fast-worsening lung disease) and anti-OJ antibodies, along with rapidly progressive lung disease, and another had coexistence of anti-CN1A and anti-NXP2 antibodies with biopsy findings that raised diagnostic complexity between inclusion body myositis and dermatomyositis. A separate case described SRP-negative necrotizing dermatomyositis with anti-NXP2 positivity and gradual improvement after corticosteroids and methotrexate, illustrating that dermatomyositis can have different biopsy patterns. [26] [24] [27]

Some reports focused on immune suppression and infection risks, including infections that were the presenting problem. A 3-patient series described dermatomyositis presenting with tuberculous infection of muscle (tuberculous pyomyositis), emphasizing diagnostic difficulty in extrapulmonary tuberculosis. Another case involved anti-MDA5 dermatomyositis with lung disease complicated by serious eye infections while on multiple immune-suppressing drugs, after which IVIG coincided with improvement in dermatomyositis activity. [25] [28]

Several reports described cancer-linked dermatomyositis where treating the cancer coincided with improvement in skin disease. One case described malignant erythema as the first sign of dermatomyositis followed by an ovarian cancer diagnosis, with rapid improvement after tumor surgery. Another case described cancer-associated clinically amyopathic dermatomyositis with anti-NXP2 antibodies and lung squamous cell carcinoma, with control of both the cancer and skin lesions after chemoradiotherapy. [29] [30]

A few cases described potential rescue approaches in severe disease and the role of advanced imaging. One critically ill patient with dermatomyositis overlapping with lupus received IVIG followed by plasma exchange and had partial strength recovery alongside a large creatine kinase reduction. Another patient improved after plasma exchange was added for rapidly progressive lung disease after earlier intensive immune therapy did not stop progression, and in a 16-year-old first diagnosed with localized scleroderma (a skin-hardening condition) who developed an inflammatory muscle disease five years later, without typical dermatomyositis features or myositis antibodies, whole-body MRI revealed extensive muscle inflammation that was not yet causing symptoms. [31] [26] [32]

One case report also described a situation where severe atopic dermatitis overlapped with dermatomyositis and where dupilumab use was reported to facilitate the biopsy diagnosis of dermatomyositis. This highlights that co-existing skin diseases can complicate recognition, and that the diagnostic pathway may change as other conditions improve. [33]

A small pediatric case series described anti-MDA5-positive juvenile dermatomyositis with interstitial lung disease and showed that disease course can be very different even within 3 children, including rapidly progressive ILD in two cases. The paper included a literature review to put these observations in context, reinforcing that this subtype needs careful attention in research, even though the report itself cannot estimate risk for most children. [34]

What this means in daily life

For patients and caregivers, these cases mainly add perspective on the range of dermatomyositis experiences, including skin-only disease, severe lung involvement, overlap syndromes, and cancer-associated presentations. They also show why antibody testing, imaging, and biopsy details sometimes become important when symptoms do not match the classic pattern. What remains uncertain is how often any single approach (like plasma exchange or IVIG in severe situations) helps across larger groups, because case reports cannot answer that. These reports are most useful for awareness and future research directions rather than predicting what will happen for a given person. [26] [31] [28] [29]